Klaus Ruckdeschel

Prof. Dr. Klaus Ruckdeschel


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2017 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
MMManoj B Menon
Manoj B Menon
JGJulia Gropengießer
Julia Gropengießer
JFJessica Fischer
Jessica Fischer
LNLena Novikova
Lena Novikova
ADAnne Deuretzbacher
Anne Deuretzbacher
KRKlaus Ruckdeschel
Klaus Ruckdeschel

15 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
YDYves Dondelinger
Yves Dondelinger
TDTom Delanghe
Tom Delanghe
DPDario Priem
Dario Priem
MWMeghan A. Wynosky-Dolfi
Meghan A. Wynosky-Dolfi
DSDaniel Sorobetea
Daniel Sorobetea
MBMathieu J. M. Bertrand
Mathieu J. M. Bertrand
RIPK1 regulates cell death and inflammation through kinase-dependent and -independent mechanisms. As a scaffold, RIPK1 inhibits caspase-8-dependent apoptosis and RIPK3/MLKL-dependent necroptosis. As a kinase, RIPK1 paradoxically induces these cell death modalities. The molecular switch between RIPK1 pro-survival and pro-death functions remains poorly understood. We identify phosphorylation of RIPK1 on Ser25 by IKKs as a key mechanism directly inhibiting RIPK1 kinase activity and preventing TNF-mediated RIPK1-dependent cell death. Mimicking Ser25 phosphorylation (S > D mutation) protects cells and mice from the cytotoxic effect of TNF in conditions of IKK inhibition. In line with their roles in IKK activation, TNF-induced Ser25 phosphorylation of RIPK1 is defective in TAK1- or SHARPIN-deficient cells and restoring phosphorylation protects these cells from TNF-induced death. Importantly, mimicking Ser25 phosphorylation compromises the in vivo cell death-dependent immune control of Yersinia infection, a physiological model of TAK1/IKK inhibition, and rescues the cell death-induced multi-organ inflammatory phenotype of the SHARPIN-deficient mice.

1 March 2011 in Infection and Immunity
Verified
Journal Article
Closed access
PDF file
KGKristin Gaus
Kristin Gaus
MHMoritz Hentschke
Moritz Hentschke
NCNicole Czymmeck
Nicole Czymmeck
LNLena Novikova
Lena Novikova
KTKonrad Trülzsch
Konrad Trülzsch
KRKlaus Ruckdeschel
Klaus Ruckdeschel
Pathogenic Yersinia species inject a panel of Yop virulence proteins by type III protein secretion into host cells to modulate cellular defense responses. This enables the survival and dissemination of the bacteria in the host lymphoid tissue. We have previously shown that YopE of the Y. enterocolitica serogroup O8 is degraded in the host cell through the ubiquitin-proteasome pathway. YopE normally manipulates rearrangements of the actin cytoskeleton and triggers phagocytosis resistance. To shed light into the physiological role of YopE inactivation, we mutagenized the lysine polyubiquitin acceptor sites of YopE in the Y. enterocolitica serogroup O8 virulence plasmid. The resulting mutant strain escaped polyubiquitination and degradation of YopE and displayed increased intracellular YopE levels, which was accompanied by a pronounced cytotoxic effect on infected cells. Despite its intensified activity on cultured cells, the Yersinia mutant with stabilized YopE showed reduced dissemination into liver and spleen following enteral infection of mice. Furthermore, the accumulation of degradation-resistant YopE was accompanied by the diminished delivery of YopP and YopH into cultured, Yersinia -infected cells. A role of YopE in the regulation of Yop translocation has already been described. Our results imply that the inactivation of YopE by the proteasome could be a tool to ensure intermediate intracellular YopE levels, which may effectuate optimized Yop injection into host cells. In this regard, Y. enterocolitica O8 appears to exploit the host ubiquitin proteasome system to destabilize YopE and to fine-tune the activities of the Yop virulence arsenal on the infected host organism.

1 February 2014 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
LNLena Novikova
Lena Novikova
NCNicole Czymmeck
Nicole Czymmeck
ADAnne Deuretzbacher
Anne Deuretzbacher
FBFriedrich Buck
Friedrich Buck
KRKathleen Richter
Kathleen Richter
KRKlaus Ruckdeschel
Klaus Ruckdeschel
Many pathogenic microorganisms have evolved tactics to modulate host cell death or survival pathways for establishing infection. The enteropathogenic bacterium Yersinia enterocolitica deactivates TLR-induced signaling pathways, which triggers apoptosis in macrophages. In this article, we show that Yersinia-induced apoptosis of human macrophages involves caspase-dependent cleavage of the TLR adapter protein MyD88. MyD88 was also cleaved when apoptosis was mediated by overexpression of the Toll–IL-1R domain–containing adapter inducing IFN-β in epithelial cells. The caspase-processing site was mapped to aspartate-135 in the central region of MyD88. MyD88 is consequently split by caspases in two fragments, one harboring the death domain and the other the Toll–IL-1R domain. Caspase-3 was identified as the protease that conferred the cleavage of MyD88 in in vitro caspase assays. In line with a broad role of caspase-3 in the execution of apoptosis, the processing of MyD88 was not restricted to Yersinia infection and to proapoptotic Toll–IL-1R domain–containing adapter inducing IFN-β signaling, but was also triggered by staurosporine treatment. The cleavage of MyD88 therefore seems to be a common event in the advanced stages of apoptosis, when caspase-3 is active. We propose that the processing of MyD88 disrupts its scaffolding function and uncouples the activation of TLR and IL-1Rs from the initiation of proinflammatory signaling events. The disruption of MyD88 may consequently render dying cells less sensitive to proinflammatory stimuli in the execution phase of apoptosis. The cleavage of MyD88 could therefore be a means of conferring immunogenic tolerance to apoptotic cells to ensure silent, noninflammatory cell demise.

17 May 2019 in Cellular Microbiology
Verified
Journal Article
Closed access
PDF file
MLMaria Jose Valencia Lopez
Maria Jose Valencia Lopez
HSHanna Schimmeck
Hanna Schimmeck
JGJulia Gropengießer
Julia Gropengießer
LMLukas Middendorf
Lukas Middendorf
MQMelanie Quitmann
Melanie Quitmann
KRKlaus Ruckdeschel
Klaus Ruckdeschel

2 October 2023 in European Journal of Cell Biology
Verified
Journal Article
Open access
LBLaura Berneking
Laura Berneking
IBIndra Bekere
Indra Bekere
SRSören Rob
Sören Rob
MSMarie Schnapp
Marie Schnapp
JHJiabin Huang
Jiabin Huang
MAMartin Aepfelbacher
Martin Aepfelbacher
The multifunctional Yersinia effector YopM inhibits effector triggered immunity and increases production of the anti-inflammatory cytokine Interleukin-10 (IL-10) to suppress the host immune response. Previously it was shown that YopM induces IL-10 gene expression by elevating phosphorylation of the serine-threonine kinase RSK1 in the nucleus of human macrophages. Using transcriptomics, we found that YopM strongly affects expression of genes belonging to the JAK-STAT signaling pathway. Further analysis revealed that YopM mediates nuclear translocation of the transcription factor Stat3 in Y. enterocolitica infected macrophages and that knockdown of Stat3 inhibited YopM-induced IL-10 gene expression. YopM-induced Stat3 translocation did not depend on autocrine IL-10, activation of RSK1 or tyrosine phosphorylation of Stat3. Thus, besides activation of RSK1, stimulation of nuclear translocation of Stat3 is another mechanism by which YopM increases IL-10 gene expression in macrophages.